The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 33, No. 7, pp. 787-789. DOI 10.1345/aph.18399
© 1999 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wyderski, R.
Right arrow Articles by Abou-Saif, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wyderski, R.
Right arrow Articles by Abou-Saif, A

Research Articles

Fatal status epilepticus associated with olanzapine therapy

RJ Wyderski, WG Starrett, and A Abou-Saif

OBJECTIVE: To report a case of fatal status epilepticus in a patient using olanzapine with no known underlying cause or predisposing factor for seizure. CASE SUMMARY: A 41-year-old white woman developed witnessed seizures at home that progressed to status epilepticus. She subsequently died from secondary rhabdomyolysis and disseminated intravascular coagulation. She had been taking olanzapine for five months prior to the event. No other toxic, metabolic, or anatomic abnormalities were identified pre- or postmortem to explain the seizures. Her seizures were a probable adverse drug reaction based on the Naranjo scale. DISCUSSION: This is the first case of fatal status epilepticus described that has been associated with the use of olanzapine. The pharmacodynamics of olanzapine are similar to those of clozapine, which has been described to induce seizures in 1-4% of patients. It is possible that this patient may have suffered seizures due to a similar effect. Alternate explanations include neuroleptic malignant syndrome and alcohol or benzodiazepine withdrawal seizures, although her clinical history does not suggest these etiologies. CONCLUSIONS: Although olanzapine has infrequently been associated with seizures in premarketing studies, its potential to induce them exists. Postmarketing surveillance should continue to determine how significant this effect may be.


This article has been cited by other articles:


Home page
 J Intensive Care MedHome page
M. K. Varma, K. Connolly, and B. Fulton
Life-Threatening Hyperglycemia and Acidosis Related to Olanzapine: A Case Report and Review of the Literature
J Intensive Care Med, January 1, 2007; 22(1): 52 - 55.
[Abstract] [PDF]

Home page
 Am. J. PsychiatryHome page
L. E. Davis, M. W. Becher, W. Tlomak, B. E. Benson, R. R. Lee, and E. C. Fisher
Persistent Choreoathetosis in a Fatal Olanzapine Overdose: Drug Kinetics, Neuroimaging, and Neuropathology
Am J Psychiatry, January 1, 2005; 162(1): 28 - 33.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
O. Dogu, S. Sevim, and H. S Kaleagasi
Seizures Associated with Quetiapine Treatment
Ann. Pharmacother., September 1, 2003; 37(9): 1224 - 1227.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
F. Centorrino, B. H. Price, M. Tuttle, W.-M. Bahk, J. Hennen, M. J. Albert, and R. J. Baldessarini
EEG Abnormalities During Treatment With Typical and Atypical Antipsychotics
Am J Psychiatry, January 1, 2002; 159(1): 109 - 115.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
J. Woolley and S. Smith
Lowered seizure threshold on olanzapine
The British Journal of Psychiatry, January 1, 2001; 178 (1): 85a - 86a.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1999 by Harvey Whitney Books Company.